Citation Impact
Citing Papers
Tumor-reactive CD4+ T cells develop cytotoxic activity and eradicate large established melanoma after transfer into lymphopenic hosts
2010 StandoutNobel
Dendritic Cell Targeting of Survivin Protein in a Xenogeneic Form Elicits Strong CD4+ T Cell Immunity to Mouse Survivin
2006 StandoutNobel
Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes
2023 Standout
Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes
2016 Standout
Bioorthogonal Chemistry: Fishing for Selectivity in a Sea of Functionality
2009 StandoutNobel
Altered immune responses in mice lacking inducible nitric oxide synthase
1995 StandoutNature
Impaired immune and acute-phase responses in interleukin-6-deficient mice
1994 StandoutNatureNobel
Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian–human immunodeficiency virus infection
2000
The Cardiovascular Biology of Glucagon-like Peptide-1
2016
Necroptosis and its role in inflammation
2015 StandoutNature
Synthesis and biological study of a flavone acetic acid analogue containing an azido reporting group designed as a multifunctional binding site probe
2005
2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention
2011 Standout
Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies
2000 Standout
Interferon‐γ and tumor necrosis factor induce the L‐arginine‐dependent cytotoxic effector mechanism in murine macrophages*
1988
Systemic administration of doxorubicin-containing liposomes in cancer patients: a phase I study
1989
Superantigen Shock In Mice With An Inapparent Viral Infection
1994 StandoutNobel
The tumour microenvironment after radiotherapy: mechanisms of resistance and recurrence
2015 Standout
Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome
2015 Standout
Cancer immunotherapy via dendritic cells
2012 Standout
Immunogenic cell death in cancer and infectious disease
2016 Standout
Efficacy and Acceptability of Glycemic Control of Glucagon-Like Peptide-1 Receptor Agonists among Type 2 Diabetes: A Systematic Review and Network Meta-Analysis
2016
The anticancer immune response: indispensable for therapeutic success?
2008
Exploiting tumour hypoxia in cancer treatment
2004 Standout
Intraarterial reteplase and intravenous abciximab for treatment of acute ischemic stroke
2005
A CAT reporter construct allows ultrasensitive estimation of TNF synthesis, and suggests that the TNF gene has been silenced in non-macrophage cell lines.
1991 StandoutNobel
Anchor extension: a structure-guided approach to design cyclic peptides targeting enzyme active sites
2021 StandoutNobel
Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review
2012
GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus
2012
A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
2015 Standout
Type 2 diabetes
2017 Standout
Polyphenols: food sources and bioavailability
2004 Standout
Plant Polyphenols: Chemical Properties, Biological Activities, and Synthesis
2011 Standout
The antitumour activity of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) in TNF receptor-1 knockout mice
2002
Doxil® — The first FDA-approved nano-drug: Lessons learned
2012 Standout
Cancer immunotherapy comes of age
2011 StandoutNature
Chemistry in living systems
2005 StandoutNobel
Abciximab and bleeding during coronary surgery: results from the EPILOG and EPISTENT trials
2000
Effects of Liraglutide Compared With Placebo on Events of Acute Gallbladder or Biliary Disease in Patients With Type 2 Diabetes at High Risk for Cardiovascular Events in the LEADER Randomized Trial
2019
Liposomal drug delivery systems: From concept to clinical applications
2012 Standout
Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
2006 Standout
Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan
2003 StandoutNature
Primary Antitumor Immune Response Mediated by CD4+ T Cells
2005
Nonspecific defence mechanism: the role of nitric oxide
1991
Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication
2011 StandoutNobel
Immunogenic cell death and DAMPs in cancer therapy
2012 Standout
New Insulins and New Aspects in Insulin Delivery
2015
Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice.
2001
Guidelines for the Early Management of Patients With Acute Ischemic Stroke
2013 Standout
Inhibition of Platelet Glycoprotein IIb/IIIa with Eptifibatide in Patients with Acute Coronary Syndromes
1998 Standout
Effects of intravenous exenatide in type 2 diabetic patients with congestive heart failure: a double-blind, randomised controlled clinical trial of efficacy and safety
2012
Patterned Hydrogels for Controlled Platelet Adhesion from Whole Blood and Plasma
2010 StandoutNobel
Open Multicentre Study of the P 2T Receptor Antagonist AR-C69931MX Assessing Safety, Tolerability and Activity in Patients with Acute Coronary Syndromes
2001
Point-of-Care Measured Platelet Inhibition Correlates With a Reduced Risk of an Adverse Cardiac Event After Percutaneous Coronary Intervention
2001
Effect of Ca 2+ on GP IIb-IIIa Interactions With Integrilin
1997
Tirzepatide Once Weekly for the Treatment of Obesity
2022 Standout
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
2014 Standout
The Current State of Peptide Drug Discovery: Back to the Future?
2017
Genetic analysis of the human tumor necrosis factor alpha/cachectin promoter region in a macrophage cell line.
1989
Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages.
1992 Standout
Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)
2018 Standout
Combination therapy with GLP ‐1 receptor agonists and basal insulin: a systematic review of the literature
2012
Highly Processable Covalent Organic Framework Gel Electrolyte Enabled by Side‐Chain Engineering for Lithium‐Ion Batteries
2021 StandoutNobel
Attainment and Maintenance of Platelet Inhibition Through Standard Dosing of Abciximab in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention
1999
Potent and synergistic neutralization of human immunodeficiency virus (HIV) type 1 primary isolates by hyperimmune anti-HIV immunoglobulin combined with monoclonal antibodies 2F5 and 2G12
1997
Once-Weekly Semaglutide in Adults with Overweight or Obesity
2021 Standout
NITRIC OXIDE AND MACROPHAGE FUNCTION
1997 Standout
Expression of interferon-beta during the triggering phase of macrophage cytocidal activation. Evidence for an autocrine/paracrine role in the regulation of this state.
1991
Safety issues with glucagon‐like peptide‐1 receptor agonists (pancreatitis, pancreatic cancer and cholelithiasis): D ata from randomized controlled trials
2017
Effects of 5,6-Dimethylxanthenone-4-Acetic Acid on Human Tumor Microcirculation Assessed by Dynamic Contrast-Enhanced Magnetic Resonance Imaging
2002
Promoter of the mouse gene encoding calcium-independent nitric oxide synthase confers inducibility by interferon gamma and bacterial lipopolysaccharide.
1993 Standout
Glucagon-Like Peptide 1 Receptor Agonist or Bolus Insulin With Optimized Basal Insulin in Type 2 Diabetes
2014
The Effects of Plant Flavonoids on Mammalian Cells:Implications for Inflammation, Heart Disease, and Cancer
2000 Standout
2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation
2015 Standout
Association of Bile Duct and Gallbladder Diseases With the Use of Incretin-Based Drugs in Patients With Type 2 Diabetes Mellitus
2016
Immunoglobulin G (IgG) and IgA, but also Nonantibody Factors, Account for In Vitro Neutralization of Human Immunodeficiency Virus (HIV) Type 1 Primary Isolates by Serum and Plasma of HIV-Infected Patients
2001 StandoutNobel
Clinical Recommendations to Manage Gastrointestinal Adverse Events in Patients Treated with Glp-1 Receptor Agonists: A Multidisciplinary Expert Consensus
2022
Optimized Human Regular U-500 Insulin Treatment Improves β-Cell Function in Severely Insulin-Resistant Patients with Long-Standing Type 2 Diabetes and High Insulin Requirements
2015
Nitric oxide as a secretory product of mammalian cells
1992 Standout
2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
2014 Standout
Multiple Defects of Immune Cell Function in Mice with Disrupted Interferon-γ Genes
1993 StandoutScience
Neutralizing Monoclonal Antibodies Block Human Immunodeficiency Virus Type 1 Infection of Dendritic Cells and Transmission to T Cells
1998 StandoutNobel
Hydrogel drug delivery system with predictable and tunable drug release and degradation rates
2013
Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors
2015
Glucocorticoid-Induced TNF Receptor Family Related Gene Activation Overcomes Tolerance/Ignorance to Melanoma Differentiation Antigens and Enhances Antitumor Immunity
2006 StandoutNobel
MANAGEMENT OF ENDOCRINE DISEASE: Are all GLP-1 agonists equal in the treatment of type 2 diabetes?
2019
Glucagon-Like Peptide-1 Receptor Agonists for Diabetes Mellitus
2014
Immunogenic Cell Death in Cancer Therapy
2012 Standout
Works of Kenneth Mace being referenced
Single‐dose pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 in healthy subjects
2014
Clinical relevance of anti‐exenatide antibodies: safety, efficacy and cross‐reactivity with long‐term treatment
2012
Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes
2008
Pharmacokinetics and Pharmacodynamics of Exenatide Extended-Release After Single and Multiple Dosing
2010
Differential inhibition of platelet aggregation induced by adenosine diphosphate or a thrombin receptor-activating peptide in patients treated with bolus chimeric 7E3 Fab: Implications for inhibition of the internal pool of GPIIb/IIIa receptors
1995
Pharmacokinetics, Pharmacodynamics, Tolerability, and Safety of Exenatide in Japanese Patients With Type 2 Diabetes Mellitus
2008
Effect of exenatide on cholecystokinin-induced gallbladder emptying in fasting healthy subjects
2012
Plasma Pharmacokinetics and Biological Activity of a Human Immunodeficiency Virus Type 1 Neutralizing Human Monoclonal Antibody, F105, in Cynomolgus Monkeys
1994
Effect of renal impairment on the pharmacokinetics of exenatide
2007
Adriamycin-induced modulation of host defenses in tumor-bearing mice.
1992
Correlation between in vivo induction of cytokine gene expression by flavone acetic acid and strict dose dependency and therapeutic efficacy against murine renal cancer.
1990
Alterations in murine host defense functions by adriamycin or liposome-encapsulated adriamycin.
1988
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Exenatide Once Weekly in Japanese Patients with Type 2 Diabetes
2009
Effect of recombinant tumor necrosis factor on tumoricidal activation of murine macrophages: synergism between tumor necrosis factor and gamma-interferon.
1987
Role of tumor necrosis factor in macrophage activation and tumoricidal activity.
1988
Steady‐state pharmacokinetics and glucodynamics of the novel, long‐acting basal insulin LY2605541 dosed once‐daily in patients with type 2 diabetes mellitus
2013
Pharmacokinetics and Pharmacodynamics of High-Dose Human Regular U-500 Insulin Versus Human Regular U-100 Insulin in Healthy Obese Subjects
2011
Discovery and development of exenatide: the first antidiabetic agent to leverage the multiple benefits of the incretin hormone, GLP-1
2012
Low incidence of anti‐drug antibodies in patients with type 2 diabetes treated with once‐weekly glucagon‐like peptide‐1 receptor agonist dulaglutide
2016